Dyadic International (NASDAQ:DYAI) Major Shareholder Sells $75,703.12 in Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 41,143 shares of the stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $1.84, for a total value of $75,703.12. Following the sale, the insider owned 3,455,764 shares of the company’s stock, valued at approximately $6,358,605.76. This represents a 1.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Dyadic International Stock Performance

Shares of NASDAQ DYAI opened at $1.00 on Thursday. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.42 and a quick ratio of 2.42. Dyadic International Inc. has a one year low of $0.65 and a one year high of $1.35. The business’s 50-day moving average price is $0.78 and its two-hundred day moving average price is $0.83. The company has a market capitalization of $36.33 million, a P/E ratio of -4.33 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The firm had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. Analysts anticipate that Dyadic International Inc. will post 0.13 earnings per share for the current fiscal year.

Institutional Trading of Dyadic International

Large investors have recently made changes to their positions in the stock. Apis Capital Advisors LLC acquired a new position in shares of Dyadic International during the 3rd quarter valued at about $1,817,000. Marathon Capital Management acquired a new stake in Dyadic International in the 3rd quarter worth approximately $41,000. Geode Capital Management LLC boosted its position in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the period. Landscape Capital Management L.L.C. bought a new stake in Dyadic International during the third quarter worth approximately $190,000. Finally, Bank of America Corp DE grew its holdings in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the last quarter. Institutional investors own 27.95% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.